ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025
The definition of atypical femoral fractures should include periprosthetic femoral fractures (PAFFs).
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology, Pathophysiology and Management of Atypical Femur Fractures: an Update.Current osteoporosis reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Periprosthetic hip fractures may have features of atypical femoral fractures. PURPOSE: Atypical femoral fracture (AFF) is a rare complication of treatment with bisphosphonates (BPs) or denosumab. The American Society for Bone and Mineral Research (ASBMR) Task Force definition for AFFs excludes periprosthetic fractures. The purpose of this study was to determine prodromal symptoms, frequency, treatment, and outcomes of periprosthetic AFFs (PAFFs) in persons prescribed a BP or denosumab for osteoporosis and later diagnosed with a periprosthetic hip fracture.
methodsParticipants were all veterans (age ≥ 50) from the VA Corporate Data Warehouse with at least one filled prescription for an oral or intravenous BP or denosumab from October 1999 through December 2022, prior to an ICD code for a periprosthetic fracture around a hip joint. Radiographs were reviewed for features of AFF. In those with a PAFF, the presence of a contralateral AFF was sought. Medical records of those with a PAFF were reviewed to identify prodromal symptoms, treatments, and outcomes.
resultsAmong approximately 400,000 veterans who received a BP or denosumab, there were 76 ICD-coded periprosthetic hip fractures, including one AFF. This fracture met all five ASMBR-defined AFF criteria. The PAFF, a Vancouver C cemented periprosthetic femur fracture, occurred in a man with > 7 years of BP therapy. There was no contralateral AFF. The BP was discontinued and the fracture was treated with an interlocking plate with cerclage wires. In the 12 months following PAFF, there were no infectious complications, but the fracture had a chronic nonunion.
conclusionPeriprosthetic hip fractures may rarely have features of AFFs. Fracture nonunion may complicate PAFFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.